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and apoptosis. This raises the intriguing possibility that 
calcium channel blockers, approved for the treatment of 
other conditions, could be repurposed to treat particular 
cancers. Further research will reveal the full extent of both 
the canonical and non-canonical functions of CaV channels 
in cancer and whether calcium channel blockers are benefi-
cial in cancer treatment.
Keywords Cancer · Calcium channels · Repurposed drugs
Introduction
Calcium signalling is an important physiological property 
of cells given the essential roles of calcium ions (Ca2+) in 
processes such as contraction, motility, apoptosis, transmit-
ter release, exocytosis and endocytosis. Cells have many 
mechanisms for the precise regulation of intracellular Ca2+ 
concentration including ion channels [TRPs and voltage-
gated calcium channels (VGCCs)], transporters and pumps 
on the plasma membrane and intracellular membranes, e.g., 
Na+/Ca2+ exchanger. VGCCs have been widely studied 
in the context of excitable cells in cardiovascular physiol-
ogy, neuromuscular physiology and neuroscience, and their 
inhibition by several classes of calcium channel blockers 
(CCBs) is important in the treatment of hypertension and 
epilepsy.
Interestingly, VGCCs are functionally expressed in 
non-excitable cells including immune cells (Vig and Kinet 
2009; Davenport et al. 2015) and a number of epithelial 
cancer cell types (Prevarskaya et al. 2010, 2014; Lastraioli 
et al. 2015; Wang et al. 2015). These cells also express 
TRP channels and it was considered that calcium signalling 
operated mainly via store-operated calcium channels, now 
defined molecularly as interactions between Orai channel 
Abstract The importance of ion channels in the hallmarks 
of many cancers is increasingly recognised. This article 
reviews current knowledge of the expression of members 
of the voltage-gated calcium channel family (CaV) in can-
cer at the gene and protein level and discusses their poten-
tial functional roles. The ten members of the CaV channel 
family are classified according to expression of their pore-
forming α-subunit; moreover, co-expression of accessory 
α2δ, β and γ confers a spectrum of biophysical charac-
teristics including voltage dependence of activation and 
inactivation, current amplitude and activation/inactivation 
kinetics. CaV channels have traditionally been studied in 
excitable cells including neurones, smooth muscle, skel-
etal muscle and cardiac cells, and drugs targeting the chan-
nels are used in the treatment of hypertension and epilepsy. 
There is emerging evidence that several CaV channels are 
differentially expressed in cancer cells compared to their 
normal counterparts. Interestingly, a number of CaV chan-
nels also have non-canonical functions and are involved in 
transcriptional regulation of the expression of other pro-
teins including potassium channels. Pharmacological stud-
ies show that CaV canonical function contributes to the fun-
damental biology of proliferation, cell-cycle progression 
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proteins on the plasma membrane and STIM proteins on 
the endoplasmic reticulum (Soboloff et al. 2012; Hogan 
et al. 2010). It is now known that a diverse array of VGCCs 
is functionally active in non-excitable cells and contribute 
to Ca2+-dependent signalling processes. In cancer cells, 
VGCCs are involved in several of the cancer hallmarks, 
originally described by Hanahan and Weinberg (2000) as 
sustaining proliferative signalling, evading growth suppres-
sors, resisting cell death, enabling replicative immortality, 
inducing angiogenesis, and activating invasion and metas-
tasis and more recently updated (Hanahan and Weinberg 
2011) to include the enabling hallmarks of reprogramming 
energy metabolism and evading immune destruction.
CaV ion channel family
The VGCC family comprises ten members, based on 
expression of a specific pore-forming α1-subunit of 190–
250 kDa containing the voltage sensor and binding sites 
for modulators and drugs and divided into three phylo-
genetic subfamilies: CaV1, CaV2 and CaV3 (Ertel et al. 
2000; Catterall 2011; Catterall et al. 2005; Alexander et al. 
2015). In the approved nomenclature ‘Ca’ represents Ca2+ 
as the main permeating ion, ‘V’ indicating the physiologi-
cal modulator, voltage and the number of the subfamily 
followed by its α1 subunit. The CaV1 subfamily includes 
CaV1.1 (α1S), CaV1.2 (α1C), CaV1.3 (α1D) and CaV1.4 (α1F), 
known as L-type channels, describing ‘long-lasting cur-
rents’, which are typically high voltage-activated and dihy-
dropyridine-sensitive. CaV2.1, CaV2.2 and CaV2.3, are high 
voltage-activated and dihydropyridine-insensitive chan-
nels which contain α1A, α1B and α1E subunits, respectively, 
mediating P/Q-type, N-type and R-type Ca2+ currents. 
CaV3 channels CaV3.1 (α1G), CaV3.2 (α1H) and CaV3.3 (α1I) 
are low voltage-activated, dihydropyridine-sensitive, T-type 
or ‘transient currents’ indicating their kinetics of activation 
and inactivation (Catterall et al. 2005). L-type and T-type 
CaV families are expressed in many cell types while N, 
P/Q, and R-type channels are predominantly expressed in 
neurons. Alternative splicing of the pore-forming α subu-
nits confers unique pharmacological and electrophysiologi-
cal properties to VGCC representing remarkable plasticity 
and molecular diversity (Hofmann et al. 1994; Tan et al. 
2011; Fan et al. 2005; Gray et al. 2007; Singh et al. 2008; 
Huang et al. 2013). It has been estimated that there are over 
1000 theoretical splice isoforms from a single α1 subunit, 
based on known splice sites (Fox et al. 2008; Emerick et al. 
2006; Gray et al. 2007).
Accessory subunits
Activity of CaV channels is modulated by co-expression 
of a number of accessory subunits, α2δ, β and γ, which 
themselves have several members, α2δ1, α2δ2, α2δ3, α2δ4, 
β, β2, β3, β4 and γ. The emerging role of these subunits 
has recently been reviewed by Hofmann et al. (2015) and 
includes essential physiological processes of channel traf-
ficking and stability in the plasma membrane in addition to 
regulation of channel activity.
Four mammalian genes have been identified for the 
α2δ1, α2δ2, α2δ3 and α2δ4 subunits, which are CAC-
NA2D1, CACNA2D2, CACNA2D3 and CACNA2D4 
respectively (Klugbauer et al. 2003; Davies et al. 2007). 
These subunits act to increase current amplitude through 
Cavα1:Cavβ complexes, modify channel gating, induce a 
hyperpolarising shift in the voltage dependence of inactiva-
tion and modulate membrane stability in addition to being 
the binding sites for the anti-epileptic drugs gabapentin and 
pregabalin (Alexander et al. 2015).
CaVβ1-4 subunits are cytosolic proteins that act to regu-
late current density by controlling the amount of α1 subu-
nit expressed at the cell membrane. In addition, β subunits 
regulate channel activation/inactivation kinetics and shift 
the voltage dependence of activation in the hyperpolarised 
direction. The CaVγ subunits, of which eight have been 
identified, are structurally similar to the skeletal muscle 
CaVγ1 subunit but γ2–8 are known to be transmembrane 
proteins involved in regulation of trafficking and gating of 
AMPA receptors and may not be linked with CaV channel 
activity (Hofmann et al. 2015).
Electrophysiological properties
The CaV subfamilies have distinctive electrophysiological 
properties reflecting their molecular composition (see Cat-
terall et al. 2005 for a comprehensive review). L-type CaV1 
currents typically activate positively to −40 mV, peak at 
0 mV in physiological solutions and show voltage depend-
ence of activation and inactivation. These long-lasting cur-
rents show slow calcium-dependent inactivation, which is 
absent when Ba2+ is the predominant charge carrier. Neu-
ronal N-type CaV2.2 channels have an intermediate volt-
age dependence and rate of inactivation that is faster than 
L-type and slower than T-type channels (Nowycky et al. 
1985; Fox et al. 2008). T-type CaV3 channels normally 
activate at more negative potentials than L-type, around 
−60 mV, peak at −20 mV and have faster kinetics of acti-
vation and inactivation.
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Pharmacology
CaV1 and CaV3 channels are sensitive to the dihydropyri-
dine class of CCBs, which includes nifedipine, nimodipine, 
nisoldipine, felodipine and isradipine and can be activated 
by dihydropyridines such as Bay K8644. These drugs, 
rather than physically blocking the pore, act allosterically 
to shift the channel toward the open or closed state (Cat-
terall et al. 2005). Within the CaV1 and CaV3 subfamilies, 
there is some differential sensitivity where CaV1.2 is more 
sensitive to nifedipine than CaV1.3 which is incompletely 
inhibited; moreover, CaV3 channels are relatively less sen-
sitive (Stengel et al. 1998). Phenylalkylamines, e.g., vera-
pamil, are intracellular pore blockers, which are thought to 
enter the pore from the cytoplasmic side of the channel and 
cause occlusion (Catterall et al. 2005). CaV1 channels are 
also sensitive to the CCB family of benzothiazepines such 
as diltiazem whereas CaV2 and CaV3 are not affected.
CaV2.2 N-type currents are insensitive to dihydro-
pyridines but can be blocked by the cone snail peptide 
ω-conotoxin GVIA and other related peptide toxins (Tsien 
et al. 1988; Olivera et al. 1994). CaV2.1 P/Q currents have 
high sensitivity to the spider toxin ω-agatoxin IVA (Mintz 
et al. 1992) whereas CaV 2.3 R-type currents exhibit resist-
ance to dihydropyridines but are sensitive to the tarantula-
derived peptide SNX-482 (Newcomb et al. 1998).
Modulators of CaV3 channels include Ni
2+ ions and the 
small molecule inhibitor mibefradil, which is widely used 
(Martin et al. 2000; Lee et al. 1999). CaV3.1 channels are 
blocked with kurtoxin, a peptide isolated from scorpion 
venom (Chuang et al.1998), although this is not selective 
as it also targets sodium channels. The diuretic amiloride 
blocks all CaV3 families with varying affinities but has 
other targets including sodium channels (Tang et al. 1988; 
Lopez-Charcas et al. 2012; Zamponi et al. 2015).
Expression of CaV in cancer
There is now compelling evidence that CaV channels are 
expressed in many cancers at the gene and protein level. 
Publically available data sets such as ONCOMINE are an 
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Fig. 1  Schematic of potential mechanisms of CaV channels in can-
cer. In many cancers, expression and function of CaV channels is 
altered. There is compelling evidence that altered CaV expression and 
function contributes to several cancer hallmarks including prolifera-
tion, apoptotic resistance, migration, invasion and enhanced cell sur-
vival. These can arise through Ca2+-dependent signalling pathways 
via influx of Ca2+ through the CaV membrane channels. In addition, 
non-canonical signalling occurs, particularly in CaV1.2 and CaV1.3 
where proteolytic cleavage of the c terminus produces a fragment that 
translocates to the nucleus and regulates the transcription of genes 
involved in processes of tumour development and progression
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excellent resource for investigation of ion channel expres-
sion from transcriptomic analyses across many studies. 
Wang et al. (2015) recently published a comprehensive 
meta-analysis of public microarray data sets reporting 
VGCC gene signatures from cancer patient samples dem-
onstrating remarkable expression of CaV genes. A signifi-
cant number of research groups have selected particular ion 
channels and characterised their functional expression with 
patch-clamp electrophysiology in primary cells derived 
from tumours or established cell lines.
CaV1.1
The CaV1.1 gene (CACNA1S) is reportedly overexpressed 
in cancer compared with normal tissues in acute myeloid 
leukaemia, brain desmoplastic medulloblastoma and neu-
roectodermal tumours (Wang et al. 2015). Furthermore, 
this study revealed that CACNA1A was among the top 5 % 
upregulated genes in the leukaemia and brain cancer data 
sets. To date, the functional expression of CaV1.1 in these 
cancers has not been investigated and this is potentially an 
exciting area of research.
CaV1.2
Overexpression of CaV1.2 (gene CACNA1C) occurs in 
many cancers including colorectal, gastric, pancreatic, 
sarcoma, leukaemia, brain, breast, uterus, skin and pros-
tate (Wang et al. 2015). This together with the finding that 
CACNA1C was in the top 10 % of upregulated genes may 
indicate involvement of CaV1.2 in common molecular 
mechanisms of definitive carcinogenic events. In human 
breast cancer MCF7 cells, increased CaV1.2 expression and 
reduced expression of the calcium binding protein, regucal-
cin, was induced by 5α-dihydrotestosterone (DHT), leading 
to reduced cell viability (Marques et al. 2015). Increased 
gene expression of CACNA1C has been reported for 
oesophageal squamous cell carcinoma, correlated with dif-
ferentiation (Shi et al. 2015); however, there is no available 
information on protein expression or ion channel function. 
Similarly, a study of gene expression data from high-grade 
serous ovarian cancer patients showed 11 copy number 
amplified genes including CACNA1C (Davis et al. 2015). 
Wang et al. (2000) reported protein expression of CAC-
NA1C, CaV1.2α, in human colon cancer tissue samples and 
in Caco-2 and T84 cells. Interestingly, Western blotting and 
immunofluorescence revealed that CaV1.2α was increased 
in non-confluent colonic cancer cells leading the authors 
to conclude that the functional expression of CaV1.2α was 
linked with proliferation.
Calcium mobilisation via L-type calcium channels such 
as Cav1.2 impacts other signalling mechanisms includ-
ing activation of large-conductance, calcium-activated 
potassium channels, BK (Prakriya and Lingle 1999; Berke-
feld et al. 2006). This is potentially important as BK chan-
nels are known to be involved in cancer biology (see the 
detailed review by Pardo and Stuhmer 2014) and CaV1.2 
therefore may indirectly drive cancer hallmarks by regulat-
ing BK channel activity.
CaV1.3
A study of the effects of nifedipine on endometrial carci-
noma Hec-1A cells showed decreased proliferation and 
migration in addition to induction of autophagy via Beclin1 
and mTOR pathways (Bao et al. 2012). The same group 
also reported expression of CACNA1D and CACNA1G in 
these cells and found that proliferation and migration were 
sensitive to mibefradil or nifedipine (Bao et al. 2012). Con-
sistent with this, CaV1.3 protein expression is reportedly 
higher in atypical hyperplasia and endometrial carcinoma 
tissues compared with benign endometrial tissue (Hao et al. 
2015). Interestingly, CaV1.3 expression was enhanced by 
17β-estradiol and its knockdown reduced the 17β-estradiol-
mediated stimulation of Ca2+ influx, proliferation and 
migration in endometrial cancer Ishikawa cells (Hao et al. 
2015). Together, this work indicates the importance of 
Ca2+ influx via CaV1.3 channels in endometrial carcinoma 
biology and further work should reveal the VGCC-related 
mechanisms underpinning this disease.
Electrophysiological patch-clamp experiments of 
MCF-7 breast cancer have demonstrated inward Ca2+ cur-
rents with the properties of both L and T-type CaV channels 
(Squecco et al. 2015). Pharmacological modulation with 
nifedipine or Ni2+ decreased cell proliferation confirming 
that CaV channels have physiological roles in breast can-
cer biology. Given that CACNA1C is known to be overex-
pressed in breast cancer tissue (Wang et al. 2015), it seems 
that CaV1.2 and one or more of the CaV3 subfamily are 
involved in the regulation of Ca2+ signalling in these cells.
CaV1.3 is co-expressed with other CaV channels and 
their subunits in a number of cancers including neuronal 
neuroblastoma cells (Park et al. 2010; Chiou 2006; Grassi 
et al. 2004; Kito et al. 1999; Neelands et al. 2000). Sousa 
et al. (2013) detected transcripts for CaV1.3, CaV2.2, 
CaV3.1 and a number of accessory subunits in SH-SY5Y 
human neuroblastoma cells. Depolarisation-induced Ca2+ 
events were nifedipine-sensitive and were also sensitive 
to the CaV2.2 inhibitors ω-conotoxins CVID, GVIA and 
MVIIA demonstrating functional activity of the channels at 
the plasma membrane. Currents with the biophysical and 
pharmacological properties of L, N- and P/Q and R type 
CaV channels have been recorded in neuroblastoma cells 
(Neelands et al. 2000) showing that these cells functionally 
express a number of distinct channels that regulate Ca2+ 
signalling. The role of this panel of CaV channels in cancer 
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hallmarks of neuroblastoma has not yet been determined 
and represents a promising area of research.
There is a compelling body of evidence that CaV1.3 
(CACNA1D) is overexpressed in prostate cancer at the 
gene and protein levels (Wang et al. 2015). Sun et al. (2006) 
reported that LNCaP prostate cancer cells displayed Ca2+ 
transients on stimulation with 5α-DHT and that these could 
be inhibited by the L-type channel inhibitors nifedipine, 
Table 1  Summary of tumour 
expression of voltage-gated 
calcium channel (CaV) members 
and their associated functions 
to date
CaV member Tumour 
expression
Function
CaV1.1 Brain, leu-
kaemia
Not defined
CaV1.2 Brain, 
breast, 
colorectal, 
gastric, 
leukaemia, 
oesopha-
geal, 
pancreatic, 
prostate, 
sarcoma, 
skin and 
uterine
Cell viability, proliferation, differentiation
CaV1.3 Breast, 
neuro-
blastoma, 
prostate, 
uterine
Proliferation, migration
CaV1.4 Testes Not defined
CaV2.1 Cervical, 
leukaemia, 
ovarian, 
brain, 
uterine, 
ovarian, 
lung
Growth progression
CaV2.2 Breast, 
neuro-
blastoma, 
prostate
Not defined
CaV2.3 Kidney, 
oesopha-
geal, 
ovarian, 
pancreatic 
and uterine
Non-canonical progression, proliferation
CaV3.1 Lung, 
pancreatic, 
neuroblas-
toma
Apoptotic resistance, autophagy, proliferation,
cell cycle
CaV3.2 Breast, 
leukaemia, 
glioblas-
toma, 
prostate
Apoptotic resistance, differentiation, proliferation, 
survival
CaV3.3 Breast, 
colon, 
oesopha-
geal, 
prostate, 
sarcoma
Proliferation
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diltiazem or verapamil. A study of CACNA1D in prostate 
cancer in the ONCOMINE database (Chen et al. 2014a) 
revealed its significant overexpression in cancer tissues 
compared with normal prostate, consistent with findings of 
CACNAID mRNA and CaV1.3 protein expression in pros-
tate cancer cell lines. Interestingly the tumour microarray 
data showed that CACNA1D gene expression was higher 
in tumours with TMPRSS2-ERG fusion, which is in agree-
ment with an epigenomic profiling study of prostate cancer 
tumours where CACNA1D was in the top-ranked differen-
tially methylated genes in tissues with the TMPRSS2-ERG 
fusion (Geybels et al. 2015). Furthermore, other studies 
have reported CACNA1D to be in the top 10–20 genes 
most significantly correlated with ERG overexpression in 
patient tissues (Setlur et al. 2008; Jhavar et al. 2009; Boor-
mans et al. 2013). In an evaluation of a panel of biomarkers 
to predict the aggressive prostate cancer phenotype, CAC-
NA1D was correlated with Gleason score and biochemical 
recurrence (Zhu et al. 2015). Interestingly, high expression 
of CACNA1D was found to be an early event in active 
surveillance biopsies but in tumours with Gleason scores 
4 + 3 or 8, CACNA1D was found to be lower. The sig-
nificance of this finding needs to be investigated in other 
cohorts and experimental cell models.
Expression of CaV1.3 in normal prostate cells is appar-
ently very low, yet there is early evidence that these cells 
utilise Ca2+-signalling pathways, perhaps via other CaV 
channels. Connor et al. (1988) reported the dependence 
of hormonally induced prostate cell death on Ca2+-influx 
pathways; moreover, Martikainen and Isaacs (1990) found 
that Ca2+-dependent processes underpinned apoptosis 
induced by androgen removal.
It is interesting to note that the expression and function 
of CaV1.2 and CaV1.3 (discussed above) can be regulated 
by oestrogen and testosterone. This observation correlates 
with the high incidence of altered expression of these chan-
nels in the female and male reproductive systems (Table 1). 
Hormonal regulation of CaV1 channels and the impact of 
this on their role in the development of particular cancers is 
a promising area for further investigation.
CaV1.4
There is limited information on the expression of CaV1.4 
(CACNA1F) in cancer. Mutations in CACNA1F cause the 
condition of incomplete congenital stationary night blind-
ness (Striessnig et al. 2010). Wang et al. (2015) reported 
overexpression of CACAN1F in testicular teratoma in their 
meta-analysis of publically available TMA; functional 
expression of the CaV1.4 protein in this or other tumours 
has not yet been reported.
CaV2.1
P/Q type channels are overexpressed in a number of cancer 
types including leukaemia, ovarian carcinoma, sarcoma, 
brain cancers, uterine corpus leiomyoma, ovarian cancer, 
lung cancers and cervical cancer (Wang et al. 2015). There 
is emerging evidence that these channels functionally 
contribute to cancer biology. Around 50–60 % of patients 
with Lambert-Eaton syndrome, an autoimmune disease 
characterised by production of autoimmune P/Q type anti-
bodies (Titulaer et al. 2011a), go on to develop small-cell 
lung cancer. This neuroendocrine cancer is known to con-
tain functional VGCCs (Titulaer et al. 2011b) and patients 
with small-cell lung cancer with low levels of P/Q antibod-
ies had poor survival compared to those of Lambert-Eaton 
syndrome with high levels of the antibody, suggesting that 
increased function of CaV2.1 P/Q channels may drive pro-
gression of the cancer (Roberts et al. 1985). This work also 
highlights the potential benefits of testing patients for the 
presence of these and other auto-immune antibodies in can-
cers that have known altered CaV expression or function.
Methylation of the CACNA1A gene is apparently asso-
ciated with several cancers. In ovarian clear cell adenocar-
cinoma, increased methylation of CACNA1A was found 
to be linked with significantly reduced progression-free 
survival (Ho et al. 2012). Moreover, in lung cancer, CAC-
NA1A has been identified as a novel tumour suppressor 
whose methylation was likely to result in adenocarcinoma 
(Castro et al. 2010). In contrast, non-methylation status of 
CACNA1A is reportedly associated with triple-negative 
breast cancer (Branham et al. 2012).
CaV2.2
CACNA1B is reported to be expressed in prostate and 
breast cancer (Wang et al. 2015). As discussed above, 
N-type CaV2.2 channels are co-expressed with CaV1 and 
CaV3 channels in neuroblastoma cells (Kito et al. 1999; 
Sousa et al. 2013). A number of papers present pharmaco-
logical data supporting the functional expression of CaV 2.2 
channels (Reeve et al. 1994; Reuveny and Narahashi 1993; 
Lambert et al. 1990; Andres et al. 2013; Morikawa et al. 
1998; and Sher et al. 1996) although at the time of some of 
the earlier studies, it may not have been possible to deter-
mine the subtype expressed. Sousa et al. (2013) found three 
splice variants of CaV2.2 in SH-SY5Y human neuroblas-
toma cells and in functional experiments observed effects 
from inhibition of CaV2.2 channels.
CaV2.3
R-type channels (CACNA1E) are reported to be signifi-
cantly overexpressed in oesophageal and uterine cancer 
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(Wang et al. 2015) although data on functional expression 
are not yet available. CACNA1E is overexpressed in child-
hood kidney cancer Wilm’s tumours, predominantly in 
the nuclei, and is associated with increased risk of relapse 
(Natrajan et al. 2006). Overexpression of CaV3.2 in HEK 
cells activated an MeK/ERK5/Nur77 pathway and may 
indicate a novel non-canonical role in cancer progression, 
which is a property of CaV1.2 and CaV1.3 channels (see 
below).
CaV2.3 channels are also involved in FSH-stimulated 
ovarian cancer cell growth (Li et al. 2007), which occurs 
via a cAMP-independent activation of ERK and is sensi-
tive to the CaV2.3 channel inhibitor, SNX-482. Functional 
CaV2.3 channels have been demonstrated in pancreatic 
cancer cells (Bon-1) where channel activity is coupled to 
IGF-1 signalling and secretion of chromogranin A (Mergler 
et al. 2003, 2005). A recent study of somatic mutations in 
patients with non-small-cell lung cancer exposed to severe 
air pollution compared with patients not exposed to pollu-
tion found that the most frequent mutations were related to 
calcium signalling, notably including CACNA1E (Yu et al. 
2015). This finding shows that CACNA1E and potentially 
other CaV channel genes can acquire mutations and act 
as drivers for certain cancers in contrast to having altered 
expression as a consequence of mutations elsewhere.
CaV3.1
Choi et al. (2014) reported anti-proliferative and apoptotic 
activities of a T-type calcium channel antagonist, BK10040, 
in human lung adenocarcinoma (A549) and pancreatic 
cancer (MiaPaCa2) cells. Consistent with this, expression 
of CACNA1G in lung cancer has been reported by Wang 
et al. (2015). In a related pharmacological study, the puta-
tive T-channel blocker KYS05090 induced autophagy- and 
apoptosis-mediated cell death in human lung adenocarci-
noma A549 cells (Rim et al. 2014) and while it decreased 
intracellular Ca2+ levels, it was not found to directly cause 
cell death. The authors reported generation of reactive oxy-
gen species and reduced glucose uptake and while the drug 
may have potential in lung cancer treatment, it might be 
independent of CaV3.1 activity. In a drug screening study 
on ovarian cancer cells, KYS05090 induced apoptosis, per-
haps confirming the functional expression of T channels 
(Jang et al. 2013).
CACNA1G is highly expressed in human laryngeal 
squamous cell carcinoma tissues and experimental cell 
lines (Yu et al. 2014); moreover, siRNA techniques and the 
CaV3 channel blocker mibefradil inhibited proliferation and 
arrested cell cycle progression. Lu et al. (2008) screened 
a panel of oesophageal cancer cell lines and found gene 
expression of CaV3.1, CaV3.2 and CaV3.3; the latter also 
confirmed by Wang et al. (2015). Functional expression 
of T currents was confirmed by patch-clamp experiments 
and their role in cancer hallmarks was demonstrated by 
the reduction of proliferation by mibefradil or by siRNA. 
As discussed above, CaV3.1 is co-expressed in SH-SY5Y 
human neuroblastoma cells along with other CaV channels 
and accessory subunits (Sousa et al. 2013).
CaV3.2
Neuroendocrine differentiation of prostate cancer cells is 
an important mechanism for the development of poor prog-
nostic tumours and is known to involve increased expres-
sion of functional CaV3.2 channels (Gackiere et al. 2008). 
In LNCaP cells, neuroendocrine differentiation evoked by 
androgen-reduced medium or cAMP increased the pro-
portion of cells expressing CaV3.2 channels (Weaver et al. 
2015a; Mariot et al. 2002), which were characterised with 
patch clamp, pharmacological blockers and siRNA (Mariot 
et al. 2002). CaV3.2 activity may act to stimulate secretion 
of mitogens and induce phenotypic change (Mariot et al. 
2002; Fukami et al. 2015). It has also been shown that 
functional coupling between BK and CaV3.2 channels may 
act to drive proliferation of prostate cancer cells (Gackiere 
et al. 2013). The involvement of the tumour microenvi-
ronment in the upregulation of CaV3.2 in neuroendocrine 
differentiation is shown in recent work by Weaver et al. 
(2015b) where IL-6 significantly increased CaV3.2 protein 
expression but did not affect mRNA expression, indica-
tive of a post-transcriptional mechanism. Interestingly IL-6 
alone did not increase the expression of functional channels 
in the membrane but co-stimulation by IL-6 and the cAMP 
agent (forskolin) did increase functional channel expres-
sion. The development of a neuroendocrine morphology 
was prevented by CaV3.2 inhibition in IL-6-stimulated cells 
confirming the channels’ role in this phenotype.
CaV channels may also be functionally expressed in leu-
kaemia and lymphoma cell lines. Mibefradil reduced cell 
growth via decreasing proliferation and promoting apopto-
sis linked with Ca2+ release from the endoplasmic reticu-
lum (Huang et al. 2015) indicating that these channels also 
participate in haematological malignancies.
The breast cancer cell line MCF-7 expresses CaV3.1 and 
CaV3.2 (Taylor et al. 2008a; Ranzato et al. 2014; Squecco 
et al. 2015), which seem to be involved in proliferation. In 
live-cell Ca2+-imaging experiments, CaV3 channel blockers 
inhibited Ca2+ transients confirming functional Ca2+ influx 
through these channels. Inhibition or knockdown of CaV 
channels inhibited MCF-7 proliferation but not that of non-
cancer breast epithelial cells; moreover, gene expression of 
CaV3.1 and CaV3.2 was only found in rapidly growing non-
confluent cells compared with confluent cells (Taylor et al. 
2008b).
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CaV3.2 channel overexpression in glioblastoma mul-
tiform tumours is apparently associated with cell survival 
and resistance to therapy (Valerie et al. 2013). Inhibition 
or knockdown of CaV3 channels was found to reduce cell 
viability and clonogenic survival and also induced apopto-
sis. Similar effects were not found with L-channel inhibi-
tion confirming that CaV3.2 channels may represent novel 
targets for treatment of glioblastomas.
CaV3.3
There are few studies reporting CACNA1I in cancer; 
however, Wang et al. (2015) found overexpression of the 
gene in breast, sarcoma and oesophageal cancers. A study 
of colon, breast and prostate cancer cells subjected to 
increased extracellular pressure reported that T-type CaV3.3 
channels modulated pressure-stimulated proliferation in all 
of the cells studied (Basson et al. 2015).
Non‑canonical functions of CaV1 channels
As highlighted above, in addition to transport of Ca2+, CaV 
channels also have non-canonical functions (Fig. 1). CaV1.2 
and CaV1.3 α subunits have carboxyl terminus regions that 
can be cleaved not only modifying the remaining pore 
subunit (Gerhardstein et al. 2000; Gao et al. 2000, 2001) 
but also conferring functions in regulation of transcription 
when the c terminus translocates to the nucleus. Wei et al. 
(1994) found that removal of up to 70 % of the CaV1.2 car-
boxyl terminus increased current density by facilitating 
coupling between voltage-dependent gating and channel 
opening, resulting in increased channel open probability. 
Cleavage of the c-terminus of CaV1.2 has been shown to 
generate a transcription factor termed CCAT (Gomez-
Ospina et al. 2006). Overexpression of the CCAT frag-
ment resulted in altered expression of a number of proteins 
including the ion channels TRPV4 and KCNN3. Therefore, 
in addition to Ca2+ flux driving cancer-related signalling, 
the CaV1.2 c-terminus can further contribute by modulat-
ing or recruiting the expression of other channels to drive 
a cancer phenotype. Cleavage of the CaV1.3 c-terminus in 
atrial myocytes is reported to induce its translocation to the 
nucleus where it acts as a transcription factor, regulating 
the expression of SK2 channels (Lu et al. 2015). In addi-
tion, expression of a number of other proteins was altered 
including immunoglobulins, transcription factors and myo-
sin light chain. Further work is required to define the genes 
regulated by actions of the c-terminus of VGCCs in differ-
ent tissues and subsequent effects on cancer progression.
Interestingly, VGCCs are known to have a number of 
protein interaction sites along their amino acid sequence, 
which allows for interaction with proteins that influence 
gene transcription such as CREB, NFAT, calmodulin and 
MEK (see the review by Barbado et al. 2009), therefore 
enabling ion channels to indirectly control transcription 
of genes that are known to be involved in cancer develop-
ment and progression (Xiao et al. 2010; Mancini and Toker 
2009; Berchtold and Villalobo 2014).
Potential of repurposing CaV drugs for cancer 
therapy
Given the functional expression of CaV channels in several 
cancers and their confirmed role in Ca2+ transport, the use 
of CCBs may be beneficial in treating the disease. Many of 
the CCBs used in experimental models are FDA approved 
for the treatment of hypertension, epilepsy, chronic pain, 
etc. Such drugs could potentially be repurposed to treat 
cancer; moreover, epidemiological evidence describes can-
cer risk in the context of CCB use for other conditions. 
Given the ability of CCBs to target multiple CaV chan-
nels, further pre-clinical research is required to determine 
whether an effect on in vivo tumours would occur.
A number of epidemiological studies have investi-
gated whether CCBs confer benefits or disadvantages in 
cancer patient cohorts. Several investigations report that 
the use of CCBs for other conditions may be correlated 
with a reduced risk of prostate cancer (Debes et al. 2004; 
Fitzpatrick et al. 2001; Lever et al. 1998; Rodriguez et al. 
2009). Furthermore, other investigations have shown that 
CCB use is associated with significantly reduced prostate 
tumour aggressiveness and development of advanced dis-
ease (Kemppainen et al. 2011; Poch et al. 2013). Similar 
studies in breast cancer (Saltzman et al. 2013) have yielded 
mixed reports of CCBs with one study showing a signifi-
cant reduction in breast cancer risk (Fitzpatrick et al. 1997), 
another reporting a trend of risk reduction (Fryzek et al. 
2006) and other studies reporting no association (Bergman 
et al. 2014; Li et al. 2003, 2013, 2014; Chen et al. 2014b, 
2015; Devore et al. 2015). In colorectal, lung and colon 
cancer, a number of studies of CCBs have shown no benefi-
cial correlation (Boudreau et al. 2008; Michels et al. 1998).
It is perhaps not surprising that the epidemiological data 
are not yet definitive as tissue cancers are a heterogene-
ous group of diseases with distinctive molecular subtypes. 
Stratification of patient data, e.g., in prostate cancer by the 
presence of the TMPRS2-ERG fusion status (Tomlins et al. 
2008) where it is known that CACNA1D is highly overex-
pressed, may show benefits of CCB use prior to develop-
ment of aggressive disease. If that were to be the case, the 
molecular pathological diagnosis of prostate tumours may 
be beneficial to stratify patients towards CCB treatment in 
addition to standard of care therapy.
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The CaV3 channel inhibitor, mibefradil, was previously 
FDA approved and used in clinical practice (Ertel and Clo-
zel 1997) but was quickly withdrawn because of serious 
toxicity arising from effects on other transporters through 
adverse interactions with beta-blockers, digoxin, vera-
pamil and diltiazem (Mullins et al. 1998). Other CCBs are 
well tolerated such as the diuretic amiloride, which also 
targets CaV3 (Tang et al. 1988), and it may be beneficial 
in the treatment of cancers where CaV3 is functionally 
overexpressed.
Drug repurposing could be enhanced by strategies that 
improve potency, selectivity and toxicity, for example the 
creation of a prodrug from linking the drug to a non-toxic 
promoiety (Karaman 2014). This strategy facilitates drug 
targeting to specific tissues with the benefits of reduc-
ing toxicity and improving selectivity by releasing the 
drug only at the target tissue site, e.g., tumour. A similar 
approach has been used with the sarcoplasmic/endoplas-
mic reticulum calcium adenosine triphosphatase (SERCA) 
pump inhibitor, thapsigargin, which has been linked to 
prostate-specific membrane antigen to direct it to prostate 
cancer cells (Denmeade et al. 2012). A similar approach 
could be used for drugs that target specific VGCCs that 
are expressed in tumour cells but that would have adverse 
effects in non-tumour cells. While this approach would take 
longer to reach clinical trial compared with simply repur-
posing existing drugs, advantages in reduced toxicity and 
better access to tumour cells would provide additional ther-
apeutic benefits.
Conclusions
The pre-clinical science and expression data reviewed 
here indicate that VGCCs are overexpressed in many can-
cers and that in the majority of cases these are functional 
channels, facilitating Ca2+ transport and homeostasis. The 
potential of CCBs in cancer treatment, in addition to chem-
otherapy, surgery and radiation therapy, has not yet been 
fully investigated through either prospective clinical trials 
or retrospective epidemiological cohort analysis. Repurpos-
ing of CCBs for the benefit of cancer patients therefore pre-
sents an attractive opportunity to improve human health.
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